



**Supplementary Fig. S8:** Identification of FDA agents that induce cytotoxicity independent of *SLC25A40-ABCB1* fusion status.

Growth rate inhibition (GR) metrics normalized to DMSO control of AOC518.5 fusion-negative (Clone D, Clone E), fusion-positive (Clone 9 and Clone 18B) and 50:50 mixed cellular populations (Clone D and Clone 9) treated with 36 FDA approved agents. GR determined through DAPI staining 72hrs post treatment (10, 5, 2.25, 0.5, 0.225, 0.05  $\mu$ M) from duplicate wells.